Aripiprazole: A review of its use in the management of mania in adults with bipolar i disorder

Drugs

Volumn 72, Issue 1, 2012, Pages 133-162

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Aripiprazole; Bipolar disorders; Manic episodes

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LITHIUM; LORAZEPAM; NORADRENALIN; OLANZAPINE; PARTIAL AGONIST; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1 AGONIST; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; AKATHISIA; BARTHOLIN GLAND; BINDING AFFINITY; BIPOLAR I DISORDER; BODY WEIGHT; CONSTIPATION; CYST; DEALKYLATION; DEHYDROGENATION; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROENCEPHALOGRAM; ETHNICITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEADACHE; HIPPOCAMPUS; HUMAN; HYDROXYLATION; HYPERGLYCEMIA; HYPEROSMOLAR COMA; HYPERTENSION; IN VIVO STUDY; INCIDENCE; INSOMNIA; ISOTOPE LABELING; KETOACIDOSIS; MAINTENANCE THERAPY; MANIA; META ANALYSIS (TOPIC); METABOLIC DISORDER; MONOTHERAPY; MUSCLE RIGIDITY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRESCRIPTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RESTLESSNESS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION; SEIZURE; SHORT COURSE THERAPY; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TABLET; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84055190591     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208320-000000000-00000     Document Type: Review

References (84)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011 Mar; 68 (3): 241-51
3. Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy 2006 Aug; 26 (8): 1134-47 (Pubitemid 44167821)
4. Ng F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009 Sep; 11 (6): 559-95
5. Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 2009 Jun; 11 Suppl. 2: 45-54
6. Goodwin GM. , on behalf of the Consensus Group of the British Association of Psycopharmacology. Evidencebased guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009 Jun; 23 (4): 346-88
7. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009 May; 11 (3): 225-55
8. Grunze H, Vieta E, Goodwin GM, et al. , on behalf of the WFSB Task Force of Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published erratum appears in World J Biol Psychiatry 2009; 10 (3): 255].
9. Keck Jr PE, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003 Apr; 12 (4): 655-62 (Pubitemid 36512009)
10. Gründer G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006 Feb; 39 Suppl. 1: S21-5 (Pubitemid 43357102)
11. Lyseng-Williamson KA, Perry CM. Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs 2004; 18 (6): 367-6; discussion 377-8
12. Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 2008; 22 (4): 335-52 (Pubitemid 351367442)
13. Fagiolini A, Nitti M, Forgione RN, et al. Aripiprazole for the treatment of bipolar disorder: a review of current evidence. Expert Opin Pharmacother 2011 Feb; 12 (3): 473-88
14. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 Jul; 302 (1): 381-9 (Pubitemid 34680462)
15. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999 Jun; 20 (6): 612-27 (Pubitemid 29189265)
16. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003 Aug; 28 (8): 1400-11 (Pubitemid 41070874)
17. Bristol-Myers Squibb. Abilify (aripiprazole): US prescribing information [online]. Available from URL: http://www. accessdata. fda. gov/drugsatfda-docs/ label/2011/021436s032, 021866s019,021713s024,021729s017lbl. pdf [Accessed 2011 Dec 9]
18. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002 Apr 26; 441 (3): 137-40 (Pubitemid 34626163)
19. Stard AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007 Feb; 190 (3): 373-82 (Pubitemid 46155646)
20. Tadori Y, Forbes RA, McQuade RD, et al. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008; 597 (1-3): 27-33
21. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metaboliteN-desmethylclozapine as aD2/D3 partial agonist. J Pharmacol Exp Ther 2005 Dec; 315 (3): 1278-87 (Pubitemid 41635416)
22. Yokoi F, Gründer G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002 Aug; 27 (2): 248-59 (Pubitemid 34692591)
23. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007 Sep; 164 (9): 1411-7 (Pubitemid 47461142)
24. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 2008 Aug; 165 (8): 988-95
25. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F] fallypride. Neuropsychopharmacology 2008 Dec; 33 (13): 3111-25
26. Jordan S, Regardie K, Johnson JL, et al. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 2007 Aug; 21 (6): 620-7 (Pubitemid 47472726)
27. Jordan S, Johnson J. L, Regardie K, et al. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacology Biol Psychiatry 2007 Mar 30; 31 (2): 348-56 (Pubitemid 46209412)
28. Zocchi A, Fabbri D, Heidbreder CA, et al. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005 Oct 28; 387 (3): 157-61 (Pubitemid 41160548)
29. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493 (1-3): 75-83 (Pubitemid 38746934)
30. Mavrikaki M, Nomikos GG, Panagis G. Efficacy of the atypical antipsychotic aripiprazole in d-amphetaminebased preclinical models of mania. Int J Neuropsychopharmcol 2010 May; 13 (4): 541-8
31. Muzina DJ. Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole. Neuropsychiatr Dis Treat 2009; 5: 279-88
32. Tadori Y, Forbes RA, McQuade RD, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 2011 Oct 15; 668 (3): 355-65
33. EuropeanMedicines Agency. Abilify (aripiprazole): summary of product characteristics [online]. Available from URL: http://www. ema. europa. eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000471/WC5000201 70. pdf [Accessed 2011 Dec 9]
34. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64 (15): 1715-36 (Pubitemid 39128008)
35. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004 Feb; 44 (2): 179-98
36. US Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www. accessdata. fda. gov/ drugsatfda-docs/nda/2002/21-436-Abilify. cfm [Accessed 2011 Oct 5]
37. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005; 45 (1): 89-93
38. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: doubleblind, randomised, comparative 12-week trial. Br J Psychiatry 2005 Sep; 187: 235-42 (Pubitemid 41306104)
39. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009 Jan; 112 (1-3): 36-49
40. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009 Jan; 194 (1): 40-8
41. Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13 (2): 133-44
42. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/ lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165 (10): 1316-25
43. El Mallakh RS, Vieta E, Rollin L, et al. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol 2010; 20 (11): 776-83
44. Keck Jr PE, Marcus R, Tourkodimitris S, et al. , on behalf of the Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003 Sep; 160 (9): 1651-8 (Pubitemid 41079552)
45. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006 Jul; 20 (4): 536-46 (Pubitemid 43875183)
46. European Medicines Agency. Assessment report for Abilify (aripiprazole): procedure no. EMEA/H/C/471/II/0039 [online]. Available from URL: http://www. ema. europa. eu/ docs/en-GB/document-library/EPAR-Assessment-Report- Variation/human/000471/WC500020167. pdf [Accessed 2011 Aug 3]
47. Suppes T, Eudicone J, McQuade R, et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008 Apr; 107 (1-3): 145-54 (Pubitemid 351288925)
48. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry 2007 Sep; 68 (9): 1377-83 (Pubitemid 47524517)
49. Frye MA, Eudicone J, Pikalov A, et al. Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials. J Clin Psychopharmacol 2008 Apr; 28 (2): 243-5 (Pubitemid 351417135)
50. Fountoulakis KN, Gonda X, Vieta E, et al. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. Ann Gen Psychiatry 2009 Dec 31; 8: 27
51. Keck Jr PE, Calabrese JR, McQuade RD, et al. , on behalf of the Aripiprazole Study Group. A randomized, doubleblind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006 Apr; 67 (4): 626-37 (Pubitemid 43764240)
52. Keck Jr PE, Calabrese JR, McIntyre RS, et al. , on behalf of the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007 Oct; 68 (10): 1480-91
53. Abilify- (aripiprazole) Data on file 092. Bristol-Myers Squibb and Otsuka America Pharmaceutical, Inc. , 2011
54. Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebocontrolled study. Int J Clin Pract 2008 May; 62 (5): 679-87 (Pubitemid 351533679)
55. El Mallakh RS, Marcus R, Baudelet C, et al. A 40-week double-blind aripiprazole versus lithium follow-up of a 12- week acute phase study (total 52 weeks) in bipolar I disorder. J Affect Disord. In press
56. Bahk W-M, Woo YS, Chung MY, et al. The efficacy and safety of aripiprazole combination with divalproex in patients with acute manic and mixed episode: a multicenter, prospective, open-label study (the SMART study) [abstract no. P-07. 003]. 27th Collegium Internationale Neuro- Psychopharmacologicum Congress; 2010 Jun 6-10; Hong Kong
57. Vieta E, Owen R, Baudelet C, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010 Jun; 26 (6): 1485-96
58. Kane JM, Barnes TRE, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol 2010 Jul; 24 (7): 1019-29
59. McIntyre RS, McElroy SL, Eudicone JM, et al. A 52-week double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord. Epub 2011 Nov 3
60. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011; 26 (1): 147-52
61. Kemp DE, Calabrese JR, Tran QV, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2010 Sep; 71 (9): 1138-44
62. Ulcickas Yood M, Delorenze G, Quesenberry CPJ, et al. Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiol Drug Saf 2010 Nov; 19 (11): 1124-30
63. Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci 2008; 10 (2): 165-79 (Pubitemid 352028219)
64. Keck Jr PE. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry 2005; 66 Suppl. 3: 5-11 (Pubitemid 40461406)
65. Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007 Sep; 9 (6): 551-60 (Pubitemid 47365622)
66. Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011 Jan; 36 (2): 375-89
67. Marken PA, Pies RW. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann Pharmacother 2006 Feb; 40 (2): 276-85 (Pubitemid 43269858)
68. Stahl SM. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Prim Care Companion J Clin Psychiatry 2003; 5 Suppl. 3: 9-13
69. Mago R. Proposed strategies for successful clinical management with aripiprazole. Expert Opin Pharmacother 2008; 9 (8): 1279-90 (Pubitemid 351877512)
70. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005; 7 Suppl. 4: 21-33 (Pubitemid 41065246)
71. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006 Apr; 67 (4): 509-16 (Pubitemid 43764227)
72. Robinson DS. Antipsychotics: pharmacology and clinical decision making. Prim Psychiatry 2007; 14 (10): 23-5 (Pubitemid 350005066)
73. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13 (1): 27-35 (Pubitemid 350275185)
74. Gentile S. Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs 2007; 21 (5): 367-87 (Pubitemid 46705301)
75. Tsai AC, Rosenlicht NZ, Jureidini JN, et al. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 2011; 8 (5): e1000434
76. Bowden CL, Calabrese JR, Sachs G, et al. A placebocontrolled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder [published erratum appears in Arch Gen Psychiatry 2004 Jul; 61 (7): 680]. Arch Gen Psychiatry 2003 Apr; 60 (4): 392-400 (Pubitemid 36403000)
77. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo- controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006 Feb; 163 (2): 247-56 (Pubitemid 44480844)
78. Vieta E. Maintenance therapy for bipolar disorder: current and future management options. Expert Rev 2004 Nov; 4 (6 Suppl. 2): S35-42 (Pubitemid 39482262)
79. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011 Oct 8; 378 (9799): 1306-15
80. Kim E, You M, Pikalov A, et al. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. BMC Psychiatry 2011; 11: 6
81. Jing Y, Johnston SS, Fowler R, et al. Comparison of secondgeneration antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder. J Med Econ 2011; 14 (6): 777-86
82. Kim E, Maclean R, Ammerman D, et al. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther 2009 Apr; 31 (4): 836-48
83. Jing Y, Kim E, You M, et al. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econ 2009; 12 (2): 104-13
84. Kasteng F, Eriksson J, Sennfält K, et al. Metabolic effects and cost-effectiveness in aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011 Sep; 124 (3): 214-25